Victory Capital Management Inc Stoke Therapeutics, Inc. Transaction History

Victory Capital Management Inc

$98.4 Billion
Q1 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$7.07 - $15.69 $8,604 - $19,094	-1,217 Reduced 6.15%	18,581 $171,000
Q3 2022 Nov 02, 2022	SELL	$12.56 - $22.53 $15,486 - $27,779	-1,233 Reduced 5.86%	19,798 $254,000
Q2 2022 Aug 01, 2022	BUY	$10.36 - $23.93 $8,360 - $19,311	807 Added 3.99%	21,031 $278,000
Q1 2022 May 04, 2022	SELL	$17.19 - $26.1 $789,828 - $1.2 Million	-45,947 Reduced 69.44%	20,224 $292,000
Q4 2021 Feb 07, 2022	BUY	$18.11 - $30.72 $229,797 - $389,806	12,689 Added 23.73%	66,171 $1.59 Million

Q3 2021 Nov 02, 2021	SELL	$23.65 - $34.44 $117,209 - $170,684	-4,956 Reduced 8.48%	53,482 $1.36 Million
Q2 2021 Aug 03, 2021	SELL	$30.53 - $41.09 $104,443 - $140,568	-3,421 Reduced 5.53%	58,438 $1.97 Million
Q1 2021 May 04, 2021	SELL	$36.08 - $69.81 $543,689 - $1.05 Million	-15,069 Reduced 19.59%	61,859 $2.4 Million
Q4 2020 Feb 01, 2021	BUY	$33.62 - $61.93 $314,414 - $579,169	9,352 Added 13.84%	76,928 $4.76 Million
Q3 2020 Nov 09, 2020	SELL	$22.23 - $37.48 $215,319 - $363,031	-9,686 Reduced 12.54%	67,576 $2.26 Million
Q2 2020 Aug 07, 2020	SELL	$20.26 - $29.73 $2.54 Million - $3.73 Million	-125,301 Reduced 61.86%	77,262 $1.84 Million
Q1 2020 May 04, 2020	BUY	$16.8 - $34.15 $384,972 - $782,547	22,915 Added 12.76%	202,563 $4.64 Million
Q4 2019 Feb 06, 2020	SELL	$20.01 - $30.79 $562,801 - $865,999	-28,126 Reduced 13.54%	179,648 $5.09 Million
Q4 2019 Feb 04, 2020	BUY	$20.01 - $30.79 $4.08 Million - $6.28 Million	203,861 Added 5209.84%	207,774 $5.81 Million
Q3 2019 Nov 12, 2019	BUY	$20.53 - $37.72 $29,008 - $53,298	1,413 Added 56.52%	3,913 $84,000
Q2 2019 Aug 15, 2019	BUY	$25.53 - $29.17 $63,825 - $72,925	2,500 New	2,500 $73,000

Others Institutions Holding STOK

# of Institutions

111

Shares Held

50M

Call Options Held

63K

Put Options Held

111K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $533M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account